Purpose: to assess long-term effectiveness of low-dose BCG in the therapy of carcinoma in situ of the bladder (CIS) Mat, and Meth.: from January 1987 to January 1995, 66 patients affected by CIS of the bladder (primary, recurrent, associated, solitary and multifocal) were treated with weekly instillations of 75 mg Pasteur strahl BCG for 6 weeks after histologic diagnosis. An additional induction course was given to patients who relapsed. Tumor-free patients followed a maintenance course with monthly instillations for 12 months. Results: at the end of the first induction course, 52/66 patients (78,7%) were tumor-free. Fourteen patients underwent a second induction course with 9/14 (64.2%) complete responses. Sixty-one patients underwent the maintenance course. At the end of the treatment, 54/66 patients (83,3%) were disease-free. After a mean observation time of 60.1 months (13-120) 47 patients (71.2%) are tumor-free, 13 (19.7%) recurred and 6 (9.1%) have progressed. The median time to first recurrence was 18 months. Median tune to progression was 13 months. No patients with primary CIS had disease progression. Eleven patients died, one from the disease and ten from other causes. Crude survival rate was 85%, disease specific mortality 1,5% and non-disease specific mortality 13,6%. The drug was well tolerated. Conclusions: Intravesical BCG is the best currently available conservative therapeutic option for patients with CIS. Its positive effect persists over time.
|Number of pages||1|
|Journal||British Journal of Urology|
|Issue number||SUPPL. 2|
|Publication status||Published - 1997|
ASJC Scopus subject areas